AKT1 is a crucial component of the signaling pathways that promote melanoma cell survival and proliferation. Conjugating anti-AKT1 antibodies to liposomes allows for targeted delivery of therapeutic agents directly to these tumor cells. This approach may inhibit key growth and survival signals, leading to reduced tumor growth and enhanced sensitivity to other treatments. Initial investigations demonstrate promise in overcoming drug resistance commonly seen in melanoma therapies.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-33-VHH | Recombinant Anti-human AKT1 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
There are currently no Customer reviews or questions for VS-1024-FY163. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.